ten23 health is a pharmaceutical CDMO (contract development and manufacturing organization). We offer solutions for the pharmaceutical industry and biotech start-ups for the development, manufacture, and testing of tomorrow’s medicines. We support our clients in developing differentiated, stable, usable, and safe injectable treatments for patients.
By 2025, we remove twice as much plastic from the environment than we send to final disposal.*
On an annual basis, by combining measures of reduction, substitution, recycling, and plastic-offsetting (removing existing plastic from the oceans with partner organizations). Final disposal means incineration or landfill.
Goal 2
In progress
Internal Operations
By 2030, we reduce our absolute greenhouse gas emissions by 42 % (Scope 1 & 2) compared with 2023, and measure and reduce our Scope 3 emissions, as part of our Science Based Targets initiative (SBTi validated goal).*
* By 2050, we reach Net Zero, reducing Scope 1, 2 & 3 emissions by 90 % compared with a 2023 base year.
Goal 3
Achieved
Internal operations
By 2023, we achieve equal treatment of all employees in the workspace, ensuring no gender pay gap.*
* Carried out by third-party assessment.
Goal 4
Achieved
Internal Operations
By 2023, we promote diversity in the workspace by targeting minimum 50% non-cis-male employees and obtaining the Swiss LGBTI label certification.*
* Carried out by third-party assessment.
Scope of pledges
ten23 health operates in Switzerland through several subsidiaries. The company is represented by ten23 health AG in Basel and Swissfillon AG in Visp. The pledges taken within the STI framework relate to the fairstainability policy applying to all ten23 health operations carried out in Switzerland. The company is therefore accountable for their implementation within the limits of its scope of activity.
